185 related articles for article (PubMed ID: 33239261)
1. Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
Zhang W; Zhang K; Yao Y; Liu Y; Ni Y; Liao C; Tu Z; Qiu Y; Wang D; Chen D; Qiang L; Li Z; Jiang S
Eur J Med Chem; 2021 Feb; 211():113022. PubMed ID: 33239261
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Bai J; Liao C; Liu Y; Qin X; Chen J; Qiu Y; Qin D; Li Z; Tu ZC; Jiang S
J Med Chem; 2016 Jun; 59(12):5766-79. PubMed ID: 27224875
[TBL] [Abstract][Full Text] [Related]
3. Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.
Clark DE; Waszkowycz B; Wong M; Lockey PM; Adalbert R; Gilley J; Clark J; Coleman MP
Bioorg Med Chem Lett; 2016 Jun; 26(12):2920-2926. PubMed ID: 27158141
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW
Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
Li J; An B; Song X; Zhang Q; Chen C; Wei S; Fan R; Li X; Zou Y
Eur J Med Chem; 2021 Feb; 212():113019. PubMed ID: 33429247
[TBL] [Abstract][Full Text] [Related]
6. In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models.
Das D; Xie L; Wang J; Shi J; Hong J
Bioorg Chem; 2020 Jun; 99():103790. PubMed ID: 32279037
[TBL] [Abstract][Full Text] [Related]
7. Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
Christensen MK; Erichsen KD; Olesen UH; Tjørnelund J; Fristrup P; Thougaard A; Nielsen SJ; Sehested M; Jensen PB; Loza E; Kalvinsh I; Garten A; Kiess W; Björkling F
J Med Chem; 2013 Nov; 56(22):9071-88. PubMed ID: 24164086
[TBL] [Abstract][Full Text] [Related]
8. SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Curtin ML; Heyman HR; Clark RF; Sorensen BK; Doherty GA; Hansen TM; Frey RR; Sarris KA; Aguirre AL; Shrestha A; Tu N; Woller K; Pliushchev MA; Sweis RF; Cheng M; Wilsbacher JL; Kovar PJ; Guo J; Cheng D; Longenecker KL; Raich D; Korepanova AV; Soni NB; Algire MA; Richardson PL; Marin VL; Badagnani I; Vasudevan A; Buchanan FG; Maag D; Chiang GG; Tse C; Michaelides MR
Bioorg Med Chem Lett; 2017 Aug; 27(15):3317-3325. PubMed ID: 28610984
[TBL] [Abstract][Full Text] [Related]
9. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
[TBL] [Abstract][Full Text] [Related]
10. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
[TBL] [Abstract][Full Text] [Related]
11. Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase.
Chen W; Dong G; He S; Xu T; Wang X; Liu N; Zhang W; Miao C; Sheng C
Bioorg Med Chem Lett; 2016 Feb; 26(3):765-768. PubMed ID: 26755394
[TBL] [Abstract][Full Text] [Related]
12. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.
Oh A; Ho YC; Zak M; Liu Y; Chen X; Yuen PW; Zheng X; Liu Y; Dragovich PS; Wang W
Chembiochem; 2014 May; 15(8):1121-30. PubMed ID: 24797455
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.
Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH
Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385
[TBL] [Abstract][Full Text] [Related]
14. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
Zhao L; Fan T; Shi Z; Ding C; Zhang C; Yuan Z; Sun Q; Tan C; Chu B; Jiang Y
Eur J Med Chem; 2021 Mar; 213():113173. PubMed ID: 33493830
[TBL] [Abstract][Full Text] [Related]
16. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Dragovich PS; Zhao G; Baumeister T; Bravo B; Giannetti AM; Ho YC; Hua R; Li G; Liang X; Ma X; O'Brien T; Oh A; Skelton NJ; Wang C; Wang W; Wang Y; Xiao Y; Yuen PW; Zak M; Zhao Q; Zheng X
Bioorg Med Chem Lett; 2014 Feb; 24(3):954-62. PubMed ID: 24433859
[TBL] [Abstract][Full Text] [Related]
17. Structure based design of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors from a phenotypic screen.
Palacios DS; Meredith E; Kawanami T; Adams C; Chen X; Darsigny V; Geno E; Palermo M; Baird D; Boynton G; Busby SA; George EL; Guy C; Hewett J; Tierney L; Thigale S; Weihofen W; Wang L; White N; Yin M; Argikar UA
Bioorg Med Chem Lett; 2018 Feb; 28(3):365-370. PubMed ID: 29275937
[TBL] [Abstract][Full Text] [Related]
18. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
Zhang B; Liu Z; Xia S; Liu Q; Gou S
Eur J Med Chem; 2021 Apr; 216():113300. PubMed ID: 33640672
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
Shaheen MA; El-Emam AA; El-Gohary NS
Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]